|
1
|
Nikiforov YE and Nikiforova MN: Molecular
genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol.
7:569–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cras A, Politis B, Balitrand N,
Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME and Chomienne
C: Bexarotene via CBP/p300 induces suppression of NF-κB-dependent
cell growth and invasion in thyroid cancer. Clin Cancer Res.
18:442–453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shoup M, Stojadinovic A, Nissan A,
Ghossein RA, Freedman S, Brennan MF, Shah JP and Shaha AR:
Prognostic indicators of outcomes in patients with distant
metastases from differentiated thyroid carcinoma. J Am Coll Surg.
197:191–197. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kimura T, Van Keymeulen A, Golstein J,
Fusco A, Dumont JE and Roger PP: Regulation of thyroid cell
proliferation by TSH and other factors: A critical evaluation of in
vitro models. Endocr Rev. 22:631–656. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu C, Zhao L, Ying H, Willingham MC and
Cheng SY: Growth activation alone is not sufficient to cause
metastatic thyroid cancer in a mouse model of follicular thyroid
carcinoma. Endocrinology. 151:1929–1939. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Davies T, Marians R and Latif R: The TSH
receptor reveals itself. J Clin Invest. 110:161–164. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cannito S, Novo E, di Bonzo LV, Busletta
C, Colombatto S and Parola M: Epithelial-mesenchymal transition:
From molecular mechanisms, redox regulation to implications in
human health and disease. Antioxid Redox Signal. 12:1383–1430.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liao WT, Song LB, Zhang HZ, Zhang X, Zhang
L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, et al: Centromere
protein H is a novel prognostic marker for nasopharyngeal carcinoma
progression and overall patient survival. Clin Cancer Res.
13:508–514. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krook KA, Fedewa SA and Chen AY:
Prognostic indicators in well-differentiated thyroid carcinoma when
controlling for stage and treatment. Laryngoscope. 125:1021–1027.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gandolfi G, de Biase D, Sancisi V, Ragazzi
M, Acquaviva G, Pession A, Piana S, Tallini G and Ciarrocchi A:
Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary
thyroid carcinomas with distant metastases. Endocr Relat Cancer.
21:L23–L26. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gandolfi G, Ragazzi M, Frasoldati A, Piana
S, Ciarrocchi A and Sancisi V: TERT promoter mutations are
associated with distant metastases in papillary thyroid carcinoma.
Eur J Endocrinol. 172:403–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cancer Genome Atlas Research Network:
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo
Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, et al:
Methylation of the thyroid-stimulating hormone receptor gene in
epithelial thyroid tumors: A marker of malignancy and a cause of
gene silencing. Cancer Res. 63:2316–2321. 2003.PubMed/NCBI
|
|
18
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deng X, Wu B, Xiao K, Kang J, Xie J, Zhang
X and Fan Y: MiR-146b-5p promotes metastasis and induces
epithelial-mesenchymal transition in thyroid cancer by targeting
ZNRF3. Cell Physiol Biochem. 35:71–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hardin H, Guo Z, Shan W, Montemayor-Garcia
C, Asioli S, Yu XM, Harrison AD, Chen H and Lloyd RV: The roles of
the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p
in papillary thyroid carcinoma progression. Am J Pathol.
184:2342–2354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Braun J, Hoang-Vu C, Dralle H and
Hüttelmaier S: Downregulation of microRNAs directs the EMT and
invasive potential of anaplastic thyroid carcinomas. Oncogene.
29:4237–4244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Z, Liu ZB, Ren WM, Ye XG and Zhang
YY: The miR-200 family regulates the epithelial-mesenchymal
transition induced by EGF/EGFR in anaplastic thyroid cancer cells.
Int J Mol Med. 30:856–862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng X, Wang Z, Fillmore R and Xi Y:
MiR-200, a new star miRNA in human cancer. Cancer Lett.
344:166–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jeon MJ, Kim TY, Kim WG, Han JM, Jang EK,
Choi YM, Song DE, Yoon JH, Chung KW, Hong SJ, et al:
Differentiating the location of cervical lymph node metastasis is
very useful for estimating the risk of distant metastases in
papillary thyroid carcinoma. Clin Endocrinol (Oxf). 81:593–599.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Middendorp M and Grünwald F: Update on
recent developments in the therapy of differentiated thyroid
cancer. Semin Nucl Med. 40:145–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cooper DS, Specker B, Ho M, Sperling M,
Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, et
al: Thyrotropin suppression and disease progression in patients
with differentiated thyroid cancer: Results from the National
Thyroid Cancer Treatment Cooperative Registry. Thyroid. 8:737–744.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sugitani I and Fujimoto Y: Does
postoperative thyrotropin suppression therapy truly decrease
recurrence in papillary thyroid carcinoma? A randomized controlled
trial. J Clin Endocrinol Metab. 95:4576–4583. 2010. View Article : Google Scholar : PubMed/NCBI
|
